Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. Co. discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. Co.'s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. We show 17 historical shares outstanding datapoints in our coverage of RVPH's shares outstanding history.
Understanding the changing numbers of RVPH shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RVPH versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RVPH by allowing them to research RVPH shares outstanding history
as well as any other stock in our coverage universe. |
Free RVPH Email Alerts:
Video: Shares Outstanding Importance
